CLAAD Presents Testimony Urging the FDA Advisory Committee To Consider the Value of Abuse-Deterrent Immediate-Release Opioid Analgesics
Earlier this week, CLAAD presented testimony before a joint meeting of the U.S. Food and Drug Administration’s (FDA) Anesthetic and Analgesic Drug Products Committee and the Drug Safety and Risk Management Committee. The joint committee reviewed the abuse-deterrent properties of the proposed immediate-release formulation of benzhydrocodone and acetaminophen, KP201. CLAAD, represented by Policy Advisor, Shruti Kulkarni, urged the joint committee to consider the value of abuse-deterrent formulations for immediate-release opioids to both patients and the public as it considers KP201. CLAAD also argued that medications like KP201 can satisfy patient needs and improve public health and safety. Head here to read CLAAD’s full testimony.